Key statistics dashboard for Quince Therapeutics, Inc. (QNCX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites.
Stock Data
| Price | $27.17 |
| Market Cap | $8M |
| Beta | 1.33 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.39 |
| Price / Book | 1.54 |
| P/S | 0.00 |
| P/FCF | -0.16 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 14.52 |
| Quick Ratio | 14.52 |
| Cash Ratio | 13.64 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -8.15 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 17.69 |
| Cash per share | 18.91 |
| FCF per share | -7.66 |
| Tangible Book Value per share | 17.69 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 5 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 0.00 |